Loading clinical trials...
Loading clinical trials...
The objective of MER-101-03 is to examine the effects of two different dosing regimens of MER-101 20mg tablets versus Zometa 4mg IV infusion once-monthly therapy. The effects will be monitored on a we...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Merrion Pharmaceuticals, LLC
NCT03016741 · Castration-Resistant Prostatic Cancer, Metastatic Prostate Carcinoma, and more
NCT00570700 · Hormone-refractory Prostate Cancer, Adenocarcinoma of the Prostate, and more
NCT00082134 · Hormone-refractory Prostate Cancer
NCT01020305 · Prostate Cancer, Prostatic Neoplasms, and more
NCT00048659 · Hormone-Refractory Prostate Cancer, Prostatic Neoplasms
Birmingham Hematology & Oncology Associates, LLC
Birmingham, Alabama
Cancer Care of North Florida, P.A.
Lake City, Florida
Lakeland Regional Cancer Center
Lakeland, Florida
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions